Dunn S, Eberlein C, Yu J, Gris-Oliver A, et al. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kbeta/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. Oncogene 2022 Oct 14. pii: 10.1038/s41388-022-02482.
PMID: 36241868